Synapse - A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas

A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas Meeting Abstract

Authors:	Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; Matasar, M. J.; Palomba, M. L.; Younes, A.; Schaffer, W.; Grewal, R.; Rademaker, J.; Sauter, C. S.; Dahi, P. B.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Pulitzer, M.; Tang, L.; Ni, A.; Horwitz, S. M.
Abstract Title:	A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
Meeting Title:	58th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	128
Issue:	22
Meeting Dates:	2016 Dec 3-6
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2016-12-02
Language:	English
ACCESSION:	WOS:000394452308040
PROVIDER:	wos
DOI:	10.1182/blood.V128.22.2991.2991
Notes:	Meeting Abstract: 2991 -- Source: Wos